SoftReach integrates state-of-the-art robotics, imaging, biofabrication and neuroscience to overcome limitations of existing practice and enable the clinical translation of emerging treatments.
Objectives:
- Provide novel means of localized delivery of therapeutics in deep-brain regions involved in devastating neurological disorders (ND).
- Enhance the efficacy of pharmaceutical treatments by bypassing limitations of systemic delivery.
- Provide means to implement cell therapies, paving their way to clinical translation.
Paradigm-shifting ambition via innovation:
- Novel miniature robotic platforms that utilize real-time MRI feedback to navigate through the Central Nervous System and deliver payload carriers of therapeutics
- Novel miniature tissue construct payloads of diverse therapeutics (compounds, cells).
- Demonstrate the proposed therapeutic approach in mouse models of neurodegeneration and advanced brain phantoms.
SoftReach is Funded by a EIC Pathfinder grant, a prestigious European funding program that supports early-stage, high-risk research into visionary and breakthrough deep-tech technologies
Key impact:
- new technologies in robotics, biomaterials and targeted delivery that can lead to new treatments for major diseases.
- establishment of new business entities. innovation that drives growth in Europe.
- new infrastructure that drives further research and innovation.